The Zika virus (ZIKV) outbreak has stimulated collaborations between Brazilians, researchers from other South American countries, and scientists from around the world. The Brazilian response to the HIV/AIDS epidemic demonstrates capabilities that can be applied to the study of ZIKV and provides lessons for developing effective international infectious disease research collaborations.
While ZIKV is spreading, much attention has focused on South American countries in general and Brazil in particular. Not only was Brazil the first country to recognize fetal abnormalities and associated neurologic complications with ZIKV infection, but it also has the highest number of reported cases (World Health Organization, 2016a) . Urgent efforts are underway to understand the many dimensions of the ZIKV threat, which necessarily and appropriately involves scientists from around the world. There is well-intentioned interest from scientists and institutions eager to apply their expertise to the ZIKV emergency in South America. While collaborative research offers opportunities not only to respond to ZIKV but also to build local capacity that will be valuable both to long-standing and emerging infectious disease threats, it is important to guard against international scientists, universities, research institutes, and pharmaceutical companies wishing to pursue projects that offer little to no long-term benefit to the growing South American scientific enterprise.
The notion that international ''saviors'' are essential to fighting emerging disease outbreaks is a convenient, common narrative. Indeed, in the recent Ebola virus disease outbreak in Western Africa, the epidemic slowed once the international community organized a comprehensive response coalition, the goals of which included stopping the outbreak, partnering with stakeholders from affected communities, treating infected people, ensuring essential services, preserving stability, and preventing further outbreaks (Global Ebola Response, 2016) . As of October 2015, a total of US $8.9 billion was pledged to this effort from donor countries (Office of the United Nations Special Envoy on Ebola, 2016). These funds were desperately needed given the extremely limited healthcare infrastructure of the most affected countries; for example, Sierra Leone, Liberia, and Guinea have 2, 1, and 10 physicians per 100,000 people, respectively (Central Intelligence Agency, 2016) . Per capita health care spending in these countries averages only $125 per year (World Health Organization, 2016b) . Scientific research in these countries is similarly limited. Guinea ranks the highest among the three most Ebola affected countries, yet ranks only 167 th globally in research output (Scimago Journal & Country Rank, 2016) . Given such scarcity, pleas that ''younger scientists are needed to work in labs in the developed countries but also here on the ground, to talk with the local people, understand their needs and pain, and work bravely to fight deadly viruses like Ebola'' are resonant (Gao and Feng, 2014) . Indeed, such appeals have fueled a more than tenfold increase in the number of North American university global health programs aimed at addressing health inequalities and serving low-and medium-income countries since 2001 (Merson, 2014) . Though Brazil is in the midst of a political and economic crisis, it has an uppermiddle-income economy as defined by the World Bank (The World Bank, 2016a) and is considerably better equipped to coordinate an effective response to ZIKV both medically and scientifically than West African countries. With 189 physicians per 100,000 people (compared to 256 per 100,000 in the United States), Brazil has a public health care system that provides care to all citizens (Central Intelligence Agency, 2016) through the Unified Health System (Sistema Ú nico de Saú de, 2016).
Significant resources have already been mobilized to monitor and contain ZIKV in Brazil. As of February 2016, ZIKV is a notifiable disease. Pregnant women with suspected infection must be reported within 24 hr. The Ministry of Health has coordinated the distribution of hundreds of thousands of ZIKV nucleic acid PCR tests to its network of 27 public laboratories. Moreover, world-class specialized care is available in large cities, including Rio de Janeiro and Sã o Paulo, as well as in regional centers such as Recife, where some of the first ZIKV complications were noted. 98% of pregnant women nationwide receive at least one prenatal care visit and have births attended by skilled health staff, in contrast to the 85% who receive prenatal care and 39% who have skilled health staff present at birth in Guinea (The World Bank, 2016c The capability of Brazilian science and medicine is illustrated by its internationally acclaimed response to HIV/AIDS through the Brazilian National AIDS Program (NAP). Among low-and middleincome countries, Brazil was the first to declare access to antiretroviral therapy a universal human right in 1996. The result was a transformation in HIV/AIDS care, with 355,000 of the country's 589,000 people now diagnosed with HIV receiving antiretroviral treatment (Global AIDS Response Progress Reporting, 2016) . This coincided with dramatic clinical benefits: mortality rates have fallen by more than 50% and inpatient hospitalization days declined by more than 80%.
Accompanying the medical response to HIV/AIDS, Brazilian research has made significant contributions to the delivery of care in resource-constrained settings. In-country production of generic medications, as well as the threat of producing generic versions of patented medications, gave Brazil leverage when negotiating antiretroviral prices for treatment and prevention. Acute HIV infections are diagnosed efficiently, and CD4+ T cell counts, viral loads, and ARV resistance monitoring is available throughout the country. Indeed, the response to HIV in other Portuguese-speaking countries is modeled by, and often implemented in collaboration with, Brazilian colleagues. Brazilian scientists have also demonstrated that pre-exposure prophylaxis with ARVs is feasible even in difficult-to-reach populations (Grant et al., 2010) . Research and care have been tightly linked with civilsociety partnerships that both engage and retain patients in HIV care.
The success of the HIV/AIDS response in Brazil (Murray et al., 2014) was also a result of international collaboration throughout the epidemic, either by resource allocation (mostly from the World Bank) or scientific collaboration. In particular, Brazil has been the site of numerous landmark, critical clinical trials sponsored by the United States National Institute of Allergy and Infectious Diseases and European organizations, such as the Medical Research Council in collaboration with the Brazilian funding, and National and State agencies that have been supporting HIV/Aids, and, most recently, ZIKV research, such as the Funding Authority for Studies and Projects (FINEP), the National Council for Scientific and Technological Development (CNPq), and the Sã o Paulo and Rio de Janeiro Research Foundations (FAPESP and FAPERJ). These organizations have also provided critical pilot funding to understand ZIKV in Brazil; for example, by providing supplements to existing grants with Brazilian scientists and rapidly reviewing applications and releasing funds for immediate use. Exchanges in which Brazilian scientists perform training (e.g., 1 year foreign exchanges during PhD training programs) in the laboratories of international investigators are also extremely useful for developing local scientific expertise. The recent program Cieˆncias sem Fronteiras (Science without Borders) was particularly ambitious, aiming to train 100,000 Brazilian students and researchers in top universities, although it was downsized in 2016 in reaction to the economic crisis. Recent years have also brought ''reverse conferences'' to large Brazilian cities, where international investigators describe recent scientific advances to large groups of Brazilian scientists and health care workers for whom traveling to international conferences would be cost prohibitive. Developing and supporting a series of such conferences throughout Brazil focused on ZIKV, dengue viruses, and other locally significant pathogens would be both educational and stimulate additional collaborations.
It must be noted that Brazil is not alone among South American countries with the capability to marshal significant local medical and scientific resources to combat ZIKV. Colombia, for example, is also a medium-high income country, currently has the second-highest number of reported ZIKV infections, and has reported ZIKV-associated microcephaly cases (Butler, 2016) . In early 2016, the country established a program to closely monitor pregnant women infected with ZIKV. Many of the points described above for Brazil apply equally well to Colombia and other South American countries.
It is indisputable that Brazilian science specifically and South American science in general face challenges: bureaucracy, cumbersome regulations, lengthy delays to get supplies, limited resources, and laboratory space. But we argue that highly qualified, motivated, and enthusiastic scientists are not the primary bottleneck. South America's large size, populous urban centers, frequent intercity travel, and tropical climate means that it will likely remain a hotspot for tropical infectious diseases and, in turn, research on these pathogens in the future.
Consequently, relationships arising to study ZIKV may be only the beginning. The success of these collaborations will be contingent upon the relationships built between Brazilian scientists and their international counterparts. These relationships are most fragile in their early days, when scientists have not yet established a mutual understanding of how best to work together. Based on our experience studying HIV/AIDS and other viruses, we have identified several specific issues (Box 1) that can lead to misunderstandings, but also to more productivity, when collaborating with Brazilian scientists. Some of these may be more obvious than others but overall can impact the success of new collaborations. We urge researchers contemplating or initiating collaborations with Brazilian researchers (or indeed, researchers from other countries in South America) to carefully consider such differences from the outset to maximize the likelihood of collaborative success. In our experience, these collaborations have proven extremely successful in establishing productive scientific ties and significantly contributing to the advance of knowledge. planning. Experiments that seem ''simple'' elsewhere may require much more logistical coordination than researchers are accustomed to (e.g., ordering and receiving PCR oligonucleotides can take weeks). d Cultural and language barriers still impose some challenges, although this has been slowly decreasing as more Brazilians get familiar with the English language and more United States-based scientists learn Portuguese. These barriers go beyond vocabulary, as they also reflect cultural differences. For example, Brazilian scientists often greet one another more effusively (e.g., hugging) than is customary in the United States. Mutual reciprocal visits are key to establishing better understanding of each stakeholder's cultural norms and manners. d Transportation of samples within Brazil and internationally is expensive, time-consuming, and can require extensive administrative approvals (e.g., material transfer agreements, Brazilian Ministry of Health approvals), particularly with respect to clinical samples. There is also a directive from the Brazilian agencies to perform as much research on Brazilian samples in Brazil as possible; collaborating to perform experiments in Brazil also builds local capacity while overcoming issues associated with international shipping.
